Lycorine hydrochloride inhibits metastatic melanoma cell‐dominant vasculogenic mimicry

Liu, Ruifang; Cao, Zhifei; Tu, Jing; Pan, Yanyan; Shang, Bingxue; Zhang, Gaochuan; Bao, Meimei; Zhang, Shasha; Yang, Ping; Zhou, Quansheng

doi:10.1111/j.1755-148x.2012.01036.x

Cited by 52 publications

(47 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, not all tumors with evidence of VM expressed DSG2. It is likely that DSG2 is one of several cadherins which can contribute to VM, and indeed, previous studies have implicated VE-cadherin in this process [47, 48]. Furthermore, other members of the desmosomal cadherin family were expressed at low level in a small number of TCGA tumors, and DSG1, DSC2 and DSC3 were all significantly enriched in the DSG2 -high tumor subset.…”

Section: Discussionmentioning

confidence: 88%

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

et al. 2016

View full text Add to dashboard Cite

Tumors can develop a blood supply not only by promoting angiogenesis but also by forming vessel-like structures directly from tumor cells, known as vasculogenic mimicry (VM). Understanding mechanisms that regulate VM is important, as these might be exploitable to inhibit tumor progression. Here, we reveal the adhesion molecule desmoglein 2 (DSG2) as a novel mediator of VM in melanoma. Analysis of patient-derived melanoma cell lines and tumor tissues, and interrogation of The Cancer Genome Atlas (TCGA) data, revealed that DSG2 is frequently overexpressed in primary and metastatic melanomas compared to normal melanocytes. Notably, this overexpression was associated with poor clinical outcome. DSG2+ melanoma cells self-organized into tube-like structures on Matrigel, indicative of VM activity, which was inhibited by DSG2 knockdown or treatment with a DSG2-blocking peptide. Mechanistic studies revealed that DSG2 regulates adhesion and cell-cell interactions during tube formation, but does not control melanoma cell viability, proliferation or motility. Finally, analysis of patient tumors revealed a correlation between DSG2 expression, VM network density and expression of VM-associated genes. These studies identify DSG2 as a key regulator of VM activity in human melanoma and suggest this molecule might be therapeutically targeted to reduce tumor blood supply and metastatic spread.

show abstract

Section: Discussionmentioning

confidence: 88%

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

et al. 2016

View full text Add to dashboard Cite

show abstract

“…However, lycorine was found to induce apoptosis as well as arrest cell cycle of HL-60, KM3, K562, Hey1B cells in different phases [7,[14][15][16]. Recently, the inhibitory effect on vasculogenic mimicry of melanoma cells [17] and suppression of neovascularization of ovarian cancer Hey1B cells by lycorine were reported [16]. Many factors thus seem involved in the anticancer properties of lycorine and a clear mechanism remains to be determined.…”

Section: Introductionmentioning

confidence: 99%

Novel Lycorine Derivatives as Anticancer Agents: Synthesis and In Vitro Biological Evaluation

et al. 2014

View full text Add to dashboard Cite

Lycorine, which is the most abundant alkaloid isolated from the Amaryllidaceae family of plants, reportedly exhibits promising anticancer activities. Herein, a series of novel lycorine derivatives were synthesized and evaluated for their in vitro inhibitory activities against seven different cancer cell lines, including A549, HCT116, SK-OV-3, NCI-H460, K562, MCF-7 and HL-60. The results indicated that compounds bearing diverse amine substituents at the C-2 position demonstrated good anticancer activities. The selectivity towards different cancer cell lines of the synthesized derivatives is discussed.

show abstract

“…It is not completely clear whether VM reflects the plasticity of differentiated melanoma cells or transdifferentiation of melanoma CSC. Nonetheless, many different pharmacologic interventions have been reported to inhibit VM in various cancers [75][76][77][78][79][80][81]. Among these, thalidomide, endostatin, and lycorine hydrochloride were shown to inhibit VM specifically in melanomas [80,81].…”

Section: Vasculogenic Mimicrymentioning

confidence: 99%

“…Nonetheless, many different pharmacologic interventions have been reported to inhibit VM in various cancers [75][76][77][78][79][80][81]. Among these, thalidomide, endostatin, and lycorine hydrochloride were shown to inhibit VM specifically in melanomas [80,81]. Other compounds known to inhibit tumor VM either in vitro or in an in vivo mouse model, include: isoxanthohumol, endostar, zoledronic acid, curcumin, and a group of cellpermeable, phosphatase-stable phosphopeptide mimetic pro-drugs targeted to the SH2 domain of Stat3 [75][76][77][78][79].…”

Section: Vasculogenic Mimicrymentioning

confidence: 99%

Differentiation of Neonatal Human-Induced Pluripotent Stem Cells to Prostate Epithelial Cells: A Model to Study Prostate Cancer Development

Setaluri¹

2013

View full text Add to dashboard Cite

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 SPONSOR/MONITOR'S REPORT NUMBER(S) DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited SUPPLEMENTARY NOTES ABSTRACT:In this project we set out to establish conditions for differentiation of human neonatal foreskin skin fibroblast-derived iPSCs into prostate epithelium-like cells and identify differences in gene expression between prostate epithelial cells derived from iPSCs of Caucasian (white) and African-American (black) foreskin fibroblasts. We identified and optimized culture conditions that promote prostate epithelial cell-like differentiation of humaniPS clone, IMAR90-4. Our data show that a feeder layer of urogential mesenchymal(UGSM) cells from neonatal mouse of either gender in combination with neonatal human dermal fibroblasts induced a striking morphological changes that resembles epithelila differentiation with formation of lumen-like structures. We show requirement of components of the extracellular matrix that promote epithelial-type differentaition. Immunofluorescence and biochemivcal analyses showed expression of androgen receptor and markers of epithelial differentiation. Analyses of pluripotency marker expression by RT-PCR showed that while human dermal fibroblasts have higher constitutive expression of Nanog, Oct4 and Sox2 compared to UGSM and IMP90 cells. Preliminary studies also showed that black black fibrobalst population has higher constitutive expression of pluripotency markers than cells from white individuals. These data form the basis for underastanding the diffences in reprogramming of skin fibroblasts to iPSc, their differentiation into prostate epithelial cells and susceptibility to transformation.

show abstract

Lycorine hydrochloride inhibits metastatic melanoma cell‐dominant vasculogenic mimicry

Cited by 52 publications

References 35 publications

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

Novel Lycorine Derivatives as Anticancer Agents: Synthesis and In Vitro Biological Evaluation

Differentiation of Neonatal Human-Induced Pluripotent Stem Cells to Prostate Epithelial Cells: A Model to Study Prostate Cancer Development

Contact Info

Product

Resources

About